1076 Results for "

Bioavailability

" in MedChemExpress (MCE) Product Catalog:
Products (1076)

1076 Results for "Bioavailability" in MCE Product Catalog:

251
251 Publications Verification
製品番号: HY-15531
CAS 番号: 1257044-40-8
純度:  99.95%
別名: ABT-199; GDC-0199; RG7601
Target:  

Bcl-2 Family Autophagy

研究分野:  

Cancer

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy .
loading...
    loading...
127
127 Cited Publications
製品番号: HY-15463
CAS 番号: 152459-95-5
純度:  99.95%
別名: STI571; CGP-57148B
研究分野:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
121
121 Cited Publications
製品番号: HY-114277
CAS 番号: 2296729-00-3
純度:  99.94%
別名: AMG-510
Target:  

Ras

研究分野:  

Cancer

Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .
loading...
    loading...
89
89 Cited Publications
製品番号: HY-50878
CAS 番号: 877399-52-5
別名: PF-02341066
Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .
loading...
    loading...
89
89 Cited Publications
製品番号: HY-50878A
CAS 番号: 1415560-69-8
別名: PF-02341066 hydrochloride
Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .
loading...
    loading...
87
87 Cited Publications
製品番号: HY-10619
CAS 番号: 1038915-60-4
純度:  99.96%
別名: MK-4827
Target:  

PARP Apoptosis

研究分野:  

Cancer

Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
87
87 Cited Publications
製品番号: HY-10619B
CAS 番号: 1038915-73-9
純度:  99.99%
別名: MK-4827 tosylate
Target:  

PARP Apoptosis

研究分野:  

Cancer

Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
87
87 Cited Publications
製品番号: HY-10619A
CAS 番号: 1038915-64-8
純度:  99.41%
別名: MK-4827 hydrochloride
Target:  

PARP Apoptosis

研究分野:  

Cancer

Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
86
86 Cited Publications
製品番号: HY-10619E
CAS 番号: 1613220-15-7
純度:  99.97%
別名: MK-4827 tosylate hydrate
Target:  

PARP Apoptosis

研究分野:  

Cancer

Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
80
80 Cited Publications
製品番号: HY-15315
CAS 番号: 1187594-09-7
純度:  99.93%
別名: LY3009104; INCB028050
Target:  

JAK

研究分野:  

Inflammation/Immunology

Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.
loading...
    loading...
80
80 Cited Publications
製品番号: HY-15315A
CAS 番号: 1187595-84-1
純度:  99.97%
別名: LY3009104 phosphate; INCB028050 phosphate
Target:  

JAK

研究分野:  

Inflammation/Immunology

Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable JAK1/JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively.
loading...
    loading...
79
79 Cited Publications
製品番号: HY-N0716B
CAS 番号: 633-66-9
別名: Natural Yellow 18 sulfate
Berberine sulfate is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine sulfate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine sulfate has antineoplastic properties. The sulfate form improves bioavailability .
loading...
    loading...
76
76 Cited Publications
製品番号: HY-13318
CAS 番号: 187227-45-8
純度:  99.50%
別名: GS 4071; Ro 64-0802; Oseltamivir carboxylate
Oseltamivir acid (GS 4071), the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC50=2 nM) with activity against both influenza A and B viruses. Oseltamivir acid has an extremely weak ability to penetrate the BBB under normal physiological conditions, but its blood-brain barrier penetration is significantly enhanced under inflammatory conditions .
loading...
    loading...
74
74 Cited Publications
製品番号: HY-135853
CAS 番号: 2492423-29-5
純度:  99.85%
別名: EIDD-2801; MK-4482
研究分野:  

Infection

Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza .
loading...
    loading...
72
72 Cited Publications
製品番号: HY-10422
CAS 番号: 1009298-09-2
純度:  99.60%
Target:  

mTOR Autophagy Apoptosis

研究分野:  

Cancer

AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2 .
loading...
    loading...
71
71 Cited Publications
製品番号: HY-13323A
純度:  99.41%
Target:  

DNA/RNA Synthesis

研究分野:  

Cancer

CX-5461 dihydrochloride is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis, with IC50s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (IC50 ≥25 μM).
loading...
    loading...
68
68 Cited Publications
製品番号: HY-19323
CAS 番号: 1352226-88-0
別名: AZD6738
Target:  

ATM/ATR

研究分野:  

Cancer

Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC50 of 1 nM.
loading...
    loading...
59
59 Cited Publications
製品番号: HY-50855B
CAS 番号: 1309357-15-0
別名: CX-4945 sodium salt
Target:  

Casein Kinase Autophagy

研究分野:  

Cancer

Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
loading...
    loading...
59
59 Cited Publications
製品番号: HY-50855
CAS 番号: 1009820-21-6
別名: CX-4945
Target:  

Casein Kinase Autophagy

研究分野:  

Cancer

Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
loading...
    loading...
57
57 Cited Publications
製品番号: HY-13026
CAS 番号: 870281-82-6
純度:  99.69%
別名: CAL-101; GS-1101
Target:  

PI3K Autophagy

研究分野:  

Cancer

Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.
loading...
    loading...